Journal of the American Academy of Child & Adolescent Psychiatry
Volume 46, Issue 3 , Pages 423-428, March 2007

Is There a Role for Clozapine in the Treatment of Children and Adolescents?

Dr. Kratochvil is with the Department of Psychiatry, University of Nebraska Medical Center, Omaha; Dr. Findling is with Departments of Psychiatry and Pediatrics, University Hospitals of Cleveland/Case Western Reserve University; Dr. Frazier is with the Department of Psychiatry, Harvard Medical School, Boston; Dr. Gerbino-Rosen is with the Department of Psychiatry and Behavioral Science, Albert Einstein College of Medicine and the Bronx Children's Psychiatric Center, New York; Dr. Kranzler is with the Department of Psychiatry, Albert Einstein College of Medicine and the Bronx Children's Psychiatric Center, New York; and Dr. Kumra is with the Department of Psychiatry, University of Minnesota, Minneapolis

Accepted 28 September 2006.

To access this article, please choose from the options below

Login to an existing account or Register a new account.

  • Purchase this article for 12.00 USD (You must login/register to purchase this article)

    Online access for 24 hours. The PDF version can be downloaded as your permanent record.

  • Subscribe to this title

    Get unlimited online access to this article and all other articles in this title 24/7 for one year.

  • Claim access now

    For current subscribers with Society Membership or Account Number.

  • Visit SciVerse ScienceDirect to see if you have access via your institution.

 This is a case vignette created to exemplify a complex clinical problem and does not refer to any specific patient.This column aims to discuss practical approaches to everyday issues in pediatric pharmacotherapy. The cases and discussions specifically target aspects of clinical care related to psychopharmacology for which we do not have adequate applicable controlled trials. Given the need to address symptoms in youths with complex, severe, and comorbid disorders, recommendations are likely to be “off label” from the perspective of the U.S. Food and Drug Administration. While it is important that clinicians address psychosocial issues in the evaluation and treatment of their patients, such discussion is beyond the specific scope of this feature. These are not meant to be practice guidelines, but rather examples of thought processes that may go into pharmacotherapy decision making.Disclosure: None of the authors have conducted industry-funded studies of clozapine. Drs. Kumra, Kranzler, and Gerbino-Rosen have conducted studies of clozapine funded by the National Institute of Mental Health, but with study drug donated by Novartis. Dr. Kratochvil was previously a speaker for Novartis and has received grant support from, is a consultant to, and/or member of the speakers' bureaus of Eli Lilly, GlaxoSmithKline, Forest, Shire, Cephalon, Novartis, McNeil, Organon, AstraZeneca, and Pfizer. Dr. Findling has been a consultant to and conducted studies for Novartis, the manufacturer of Clozaril, and receives or has received research support from, acted as a consultant to, and/or served on the speakers' bureaus of Abbott, AstraZeneca, Bristol-Myers Squibb, Celltech-Medeva, Forest, GlaxoSmithKline, Johnson & Johnson, Lilly, New River, Novartis, Otsuka, Pfizer, Sanofi-Aventis, Shire, Solvay, and Wyeth. Dr. Frazier has received research support from, acted as a consultant to, and/or served on the speakers' bureaus of AstraZeneca, Bristol-Myers Squibb, Eli Lilly, Forest Research Institute, Johnson & Johnson Pharmaceutical Research and Development, Otsuka Pharmaceutical Inc., and Pfizer. The other authors have no financial relationships to disclose.

PII: S0890-8567(09)61687-7

doi:10.1097/chi.0b013e3180ed94e

Journal of the American Academy of Child & Adolescent Psychiatry
Volume 46, Issue 3 , Pages 423-428, March 2007

Article Tools